New York, NY, New Orleans, LA (PRWEB) October 30, 2008
Shiel Medical Laboratory will be demonstrating its unique Oxidized LDL/HDL Ratio Test to cardiologists and cardiology researchers at the American Heart Association's Scientific Sessions in New Orleans, November 8-11, 2008, at Booth No. 3100. As part of the demonstration, the Oxidized LDL/HDL Ratio Test and the traditional lipid panel containing total cholesterol, triglycerides, LDL-cholesterol and HDL will be drawn and performed on conference attendees' blood samples. The demonstration will enable cardiologists and researchers to compare their traditional coronary artery disease risk assessment results with the Oxidized LDL/HDL Ratio Test.
The development of the Oxidized LDL/HDL Ratio Test is the result of a long and arduous process. It began with an idea developed by Professor Daniel Steinberg in the late 1980s which stated that for LDL to be atherogenic and directly involved in the atherosclerotic disease process, it must first be converted to oxidized LDL. The next step came when Professor Paul Holvoet of Leuven, Belgium, invented in the 1990s an ELISA (Enzyme-Linked-ImmunoSorbent Assay) test with a specific monoclonal antibody (mAb-4E6) for oxidized LDL. Mercodia, a Swedish diagnostic kit manufacturer, in 1999 developed and manufactured a robust ELISA kit for measuring blood levels of oxidized LDL using Professor Holvoet's monoclonal antibody for oxidized LDL. The last phase of this important process was the introduction of the Oxidized LDL/HDL Ratio Test to the US medical marketplace by Shiel Medical Laboratory in 2007.
The efficacy of the oxidized LDL ELISA test has been proven in a well-documented study by Dr. Nina Johnston and her colleagues at Uppsala University and published in the American Journal of Cardiology in 2006. This study clearly demonstrates that the oxidized LDL/HDL ratio is the best single blood lipid biomarker for discriminating between coronary artery disease patients and healthy control subjects.
In additional verification of the test's efficacy, Harold M. Bates, Ph.D. of Shiel Medical Laboratory, who has been directly involved with the development of the test since 1996, further analyzed the data of Nina Johnston et al and found that the Oxidized LDL/HDL Ratio Test could indeed identify 52 percent more patients with documented coronary artery disease than the LDL-cholesterol test.
Oxidized LDL is a plaque-specific protein involved in all stages of coronary artery disease. Oxidized LDL is found only in atherosclerotic plaques and not in normal artery walls. The CAD process cannot initiate or progress until the oxidation of LDL occurs. Oxidized LDL is the atherogenic form of LDL and is responsible for the deposition of plaque in arteries. HDL is anti-atherogenic and removes plaque. The Oxidized LDL/HDL Ratio is the only blood test that reflects atherosclerotic disease activity in the artery wall.
At present, the LDL-cholesterol test is still the standard of care, but by adding the Oxidized LDL/HDL ratio test, physicians can make better decisions on how aggressively or non-aggressively to treat a patient with borderline results. It will also help identify patients that may not be clearly indicated by the lipid panel who are at risk. The new OxLDL/HDL ratio test is another important tool for cardiac health evaluation, which in time may become the standard of care in CAD risk assessment and CAD treatment follow-up.
About Shiel Medical Laboratory
In business since 1919, Shiel Medical Laboratory's main lab facility is located in the historic Brooklyn Navy Yard. Its 35,000 square foot laboratory allows Shiel to service clientele with the highest level of efficiency and accuracy while maintaining their position as the fastest growing regional laboratory in the New York Metropolitan area. Shiel's state-of-the-art facility provides physicians and patients with an expansive range of clinical laboratory testing services. Shiel's commitment to accuracy, reliability and efficiency makes it a respected choice for quality clinical diagnostics.